Maraviroc

BreastfeedingGeriatricPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Clarithromycin, Conivaptan, CYP3A4 inhibitors or inducers, Darunavir, Dasatinib, Deferasirox, Delavirdine, Efavirenz, Etravirine, Indinavir, Ketoconazole, Lopinavir, Nelfinavir, Oxcarbazepine, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole

PREGNANCY CATEGORY: B

HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Our database has 40 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of maraviroc in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/15/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top